Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 1,695 Shares

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 1,695 shares of the company’s stock in a transaction on Monday, April 29th. The shares were sold at an average price of $6.38, for a total value of $10,814.10. Following the completion of the transaction, the chief financial officer now owns 339,803 shares of the company’s stock, valued at $2,167,943.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Thomas Catinazzo also recently made the following trade(s):

• On Wednesday, March 27th, Thomas Catinazzo sold 348 shares of Relay Therapeutics stock. The shares were sold at an average price of $7.70, for a total value of $2,679.60.

Relay Therapeutics Price Performance

Relay Therapeutics stock opened at $6.59 on Tuesday. The company has a market cap of $872.12 million, a price-to-earnings ratio of -2.35 and a beta of 1.63. Relay Therapeutics, Inc. has a 12 month low of $5.70 and a 12 month high of $13.32. The stock’s 50-day moving average is $8.15 and its 200-day moving average is $8.81.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.09. Relay Therapeutics had a negative net margin of 1,263.49% and a negative return on equity of 42.43%. During the same period last year, the business earned ($0.56) EPS. Research analysts anticipate that Relay Therapeutics, Inc. will post -2.84 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on RLAY shares. Stifel Nicolaus increased their price objective on shares of Relay Therapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Leerink Partnrs reaffirmed an “outperform” rating on shares of Relay Therapeutics in a research note on Thursday, February 22nd. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $26.00.

Hedge Funds Weigh In On Relay Therapeutics

A number of hedge funds have recently made changes to their positions in RLAY. Allspring Global Investments Holdings LLC purchased a new stake in Relay Therapeutics during the 1st quarter worth $79,000. Victory Capital Management Inc. acquired a new position in shares of Relay Therapeutics during the fourth quarter worth about $126,000. Quest Partners LLC purchased a new stake in shares of Relay Therapeutics in the fourth quarter worth about $147,000. Los Angeles Capital Management LLC grew its stake in shares of Relay Therapeutics by 25.7% in the first quarter. Los Angeles Capital Management LLC now owns 13,939 shares of the company’s stock valued at $116,000 after buying an additional 2,850 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Relay Therapeutics by 354.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,257 shares of the company’s stock valued at $157,000 after buying an additional 11,122 shares in the last quarter. Hedge funds and other institutional investors own 96.98% of the company’s stock.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.